A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

Stopped early · Not applicable

Conditions studied: Obesity, Hypertension

In brief

Obesity and hypertension are independent risks for congestive heart failure (CHF) and chronic kidney disease. In obesity induced hypertension, the most common cause of human essential hypertension, the potential importance of mineralocorticoid receptor blockade has not been widely investigated. We propose to test the hypothesis that eplerenone reduces metabolic demand, improves cardiac function and attenuates glomerular hyperfiltration and microalbuminuria in obese patients. Our specific aims are to assess changes in basal metabolic rate, cardiac and renal function in obese hypertensive subjects treated with eplerenone compared to amlodipine.

Key facts

Study ID

NCT00825188

Run by

University of Mississippi Medical Center

People needed

10

Starts

2009-01-01

Expected to finish

2014-03-01

Last updated by the study team

2018-05-29

Who can join

Age: 21 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Systolic blood pressure (SBP) between 140 and 160 mmHg and/or a diastolic blood pressure between 90 and 100 mmHg who also have a body mass index > 30-45.
• Women must be post menopausal

You may not qualify if…

• Women of child bearing potential
• BMI less than 30 or greater than 45
• A creatinine > 1.8 for females and > 2.0 for males
• Type 1 or type 2 diabetes
• Current evidence of alcohol or drug abuse problems

Where it is running

• The University of Mississippi Clinical Research Program — Jackson, Mississippi, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.